NCT03792347View on ClinicalTrials.gov

Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

March 17, 2020

Study Completion Date

June 17, 2020

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Pembrolizumab

Arm1：Pre-operative Pembrolizumab+chemoradiotherapy

Trial Locations (1)

200025

Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

All Listed Sponsors
lead

Hecheng Li M.D., Ph.D

OTHER

NCT03792347 - Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus | Biotech Hunter | Biotech Hunter